van Christiansen, MD
Family Medicine · Pleasant View, UTNPI 1093702672
Payments from drug & device makers
Across 141 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$253
- GSK$198
- Astellas Pharma US Inc$197
- Pfizer$139
- Dynavax Technologies Corporation$97
- Merck$78
- plus $1K from 34 others
What the payments were for
- Food & beverage$2,210100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $253 |
| GSK | 13 | $198 |
| Astellas Pharma US Inc | 12 | $197 |
| Pfizer | 8 | $139 |
| Dynavax Technologies Corporation | 7 | $97 |
| Merck | 4 | $78 |
| Baxter Healthcare | 2 | $76 |
| Lilly USA, LLC | 5 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Amarin Pharma, Inc. | 5 | $67 |
| Ironshore Pharmaceuticals Inc. | 4 | $60 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Organon | 7 | $59 |
| Johnson & Johnson | 4 | $59 |
| Amgen(2 entities) | 4 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Sanofi Pasteur Inc. | 3 | $48 |
| Boston Scientific | 2 | $45 |
| Corium, LLC | 2 | $43 |
| AstraZeneca | 3 | $43 |
| Intuitive Surgical | 1 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Sobi, Inc | 2 | $31 |
| Tris Pharma Inc | 2 | $25 |
| Abbott | 1 | $24 |
| Shire North American Group Inc | 2 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Sanofi | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| BD | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| Treace Medical Concepts, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Qiagen, LLC | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $11 |
| Adlon Therapeutics L.p. | 1 | $11 |
| Bayer | 1 | $11 |
How this compares
$2,210 in reported general payments places this provider in the 70th percentile of 928 family medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $34,149 |
| FarxigaDapagliflozin Propanediol | 35 | $32,031 |
| XareltoRivaroxaban | 30 | $25,193 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $13,821 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,527 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $7,750 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $7,360 |
| Omeprazole | 221 | $4,153 |
| Levothyroxine Sodium | 268 | $3,355 |
| Atorvastatin Calcium | 356 | $2,803 |
| Entacapone | 13 | $2,569 |
| Metformin Hcl | 209 | $2,526 |
| Gabapentin | 97 | $2,132 |
| SynthroidLevothyroxine Sodium | 21 | $1,791 |
| Potassium Chloride | 70 | $1,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $139 | $34,14928 claims |
| AstraZenecaFarxiga | $43 | $32,03135 claims |
| Johnson & JohnsonXarelto | $59 | $25,19330 claims |
| GSKTrelegy Ellipta | $198 | $10,52715 claims |
| AbbVieSynthroid | $253 | $1,79121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 928 family medicine providers in Utah.
Other family medicine in Pleasant View
- Darek EgglestonPleasant View$2.8M
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
- Sarang YoonSalt Lake City$9.4M
- Michael AdamsSandy$8.1M
- Katie JulienSouth Jordan$7.1M
- Scott EricksonBountiful$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.